NORYVA
Designed to touch one thing where its elders touched several.
10 mg
Ipamorelin is an entirely artificial molecule, designed to aim at a single target where older molecules in its family hit several at once. It is this precision that makes it a subject of study.
The same reference, in pen format
The molecule is delivered in a sealed cartridge, inside a refillable anodised aluminium pen. It is not an accessory to add on: it is the other way of ordering the same reference, at its own price.
Why did its development stop?
It stopped, and we will not tell that story on its behalf: the human data that exist are old, and no file was carried to completion. It is the most important limit on this page, which is why it is written here and not at the bottom.
Older molecules in the same family touched several targets at once. This one was drawn to aim at a single one. That precision is what is studied — and it is also all the available work allows one to say: clinical development stopped, and the human data that exist are old.
Ipamorelin is a synthetic pentapeptide, an agonist of the ghrelin receptor (GHS-R1a). It is an entirely artificial molecule: it does not occur in the body.
The ghrelin receptor takes part in regulating growth-hormone release. Ipamorelin is used to study that pathway with a selectivity older molecules did not have.
Proposed mechanism: selective agonism of the GHS-R1a receptor. The selectivity described in the literature concerns experimental models, not a practice.
Older clinical studies exist, run for specific indications over short durations. They do not transfer to another setting.
Animal data on selectivity and growth-hormone release.
Clinical development discontinued; no marketing authorisation. Old human data are not current data.
For laboratory research purposes only. Not for human consumption or therapeutic use.
This reference holds no marketing authorisation as a medicinal product.
No. This reference is not offered for sale: its commercial framework is not settled. No purchase button is shown until it is.
No. This reference holds no marketing authorisation as a medicinal product and is approved by no authority for human use. A publication or a clinical trial never amounts to approval.
The certificate of analysis is supplied with the batch delivered. No batch number or purity figure is published until the real certificate has been entered: we do not display illustrative values.
The storage requirement is not yet on file: the supplier data sheet has not reached us. We would rather say so than assume.
Compatibility is not confirmed for this reference. Until the manufacturer confirms it, we do not claim it.
Clinical development discontinued; no marketing authorisation. Old human data are not current data.
Conversion not published
How a graduation on the NORYVA pen maps to a volume depends on its mechanism. Its technical sheet is not on file: no conversion is shown until the manufacturer confirms it. We would rather write that than assume it.